Needham analyst Gil Blum has maintained their bullish stance on AUTL stock, giving a Buy rating on October 27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum has given his Buy rating due to a combination of factors related to the promising clinical data from Autolus Therapeutics. The recent update on the first six patients demonstrated sustained complete response rates in half of the patients and significant responses in five out of six, indicating a strong potential for the therapy’s effectiveness. Furthermore, the resolution of non-renal manifestations within four months and the meaningful reduction in disease activity scores in most patients highlight the therapy’s impact.
Additionally, the consistent reduction in ds-DNA antibodies and normalization of C3 measures in all patients further support the therapy’s efficacy. The extended duration of B-cell aplasia observed in these patients, compared to other CAR-T products, suggests a possibility of more durable clinical responses, although this remains to be confirmed. These positive clinical outcomes, along with anticipated data updates, underpin the Buy rating, reflecting confidence in the company’s therapeutic advancements.